MedPath

Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy

Phase 3
Completed
Conditions
Breast Cancer
Hot Flashes
Interventions
Registration Number
NCT00087399
Lead Sponsor
Alliance for Clinical Trials in Oncology
Brief Summary

RATIONALE: Gabapentin may be effective in relieving hot flashes in women who have had breast cancer or who have concerns about taking hormone therapy to treat hot flashes. It is not yet known whether gabapentin is more effective with or without antidepressants in treating hot flashes.

PURPOSE: This randomized phase III trial is studying gabapentin and antidepressants to see how well they work compared to antidepressants alone in treating hot flashes in women who have had breast cancer or who have concerns about taking hormones to treat hot flashes.

Detailed Description

OBJECTIVES:

* Compare the efficacy of gabapentin with vs without an antidepressant, as measured by the frequency and intensity of hot flashes, in patients with a history of breast cancer or a concern about taking hormonal therapy due to a fear of developing breast cancer.

* Compare adverse events in patients treated with these regimens.

* Correlate a reduction in hot flash scores with improvement in quality of life and related outcomes in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to duration of hot flash symptoms (\< 9 months vs ≥ 9 months), average frequency of hot flashes per day (2-3 vs 4-9 vs ≥ 10), and antidepressant currently being used (venlafaxine vs paroxetine vs other). Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.

* Arm II: Patients receive gabapentin as in arm I. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone (per arm I schedule).

Patients in both arms complete a hot flash diary at baseline and then daily during study treatment.

Quality of life is assessed at baseline and then weekly during study treatment.

PROJECTED ACCRUAL: A total of 110 patients (55 per treatment arm) will be accrued for this study within 2 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
118
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
gabapentin + antidepressantgabapentinPatients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients complete a hot flash diary at baseline and then daily during study treatment.
gabapentin + antidepressantantidepressantPatients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients complete a hot flash diary at baseline and then daily during study treatment.
gabapentingabapentinPatients receive gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone. Patients complete a hot flash diary at baseline and then daily during study treatment.
Primary Outcome Measures
NameTimeMethod
Hot flash reduction by diary record at 4 weeksat 4 weeks
Secondary Outcome Measures
NameTimeMethod
Toxicity by questionnaires at 4 weeksat 4 weeks

Trial Locations

Locations (162)

CCOP - Mayo Clinic Scottsdale Oncology Program

🇺🇸

Scottsdale, Arizona, United States

Mayo Clinic - Jacksonville

🇺🇸

Jacksonville, Florida, United States

MBCCOP-Medical College of Georgia Cancer Center

🇺🇸

Augusta, Georgia, United States

Rush-Copley Cancer Care Center

🇺🇸

Aurora, Illinois, United States

St. Joseph Medical Center

🇺🇸

Bloomington, Illinois, United States

Graham Hospital

🇺🇸

Canton, Illinois, United States

Memorial Hospital

🇺🇸

Carthage, Illinois, United States

Eureka Hospital

🇺🇸

Eureka, Illinois, United States

Galesburg Clinic

🇺🇸

Galesburg, Illinois, United States

Galesburg Cottage Hospital

🇺🇸

Galesburg, Illinois, United States

Scroll for more (152 remaining)
CCOP - Mayo Clinic Scottsdale Oncology Program
🇺🇸Scottsdale, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.